Breaking News
October 24, 2018 - Spectrum Pharmaceuticals Receives FDA Approval of Khapzory (levoleucovorin) for Injection
October 24, 2018 - Researcher uses smartphone to detect breast cancer gene
October 24, 2018 - Advanced breast cancer patients can benefit from immunotherapy-chemotherapy combination
October 24, 2018 - Stress related to social stigma negatively impacts mental health of autistic people
October 24, 2018 - New 17-item questionnaire may help detect GI disorders in children with autism
October 24, 2018 - 12% of frequent marijuana smokers experience cannabis withdrawal syndrome
October 24, 2018 - Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis
October 24, 2018 - Poor Experience With PCP Linked to Hospitalization in CKD
October 23, 2018 - Dummies not to blame for common speech disorder in kids
October 23, 2018 - The future of ethics and biomedicine: An interview
October 23, 2018 - X4 Pharmaceuticals announces clinical data of X4P-001-IO and Opdivo in patients with clear cell renal cell carcinoma
October 23, 2018 - FDA targets 465 websites that sell potentially dangerous, unapproved drugs
October 23, 2018 - New approach may lead to better diagnostic techniques for autoimmune disorders
October 23, 2018 - Innovative computer software sheds new light on genetic processes underlying deadly diseases
October 23, 2018 - Juul Drawing Lots of Teen Followers on Twitter
October 23, 2018 - WHO says Zika risk low in Pacific ahead of Meghan visit
October 23, 2018 - A deeper look at ‘Reflecting Frankenstein’
October 23, 2018 - Breastfeeding can have protective affect against high blood pressure in women, confirms study
October 23, 2018 - Epigenetic modifications may contribute to Alzheimer’s Disease
October 23, 2018 - Volunteering for peer counseling programs benefits people with lupus
October 23, 2018 - Cancer treatment may undergo a paradigm shift to immunotherapy soon
October 23, 2018 - Study uncovers new mechanism of action in a first-line drug for diabetes
October 23, 2018 - New type of molecule shows early promise against treatment-resistant prostate cancer
October 23, 2018 - Lancet publishes pioneering study of Aimovig’s efficacy in episodic migraine patients
October 23, 2018 - Scientists grow functioning human neural networks in 3D from stem cells
October 23, 2018 - Using mushrooms as a prebiotic may help improve glucose regulation
October 23, 2018 - New ENT clinic treats children in Zimbabwe
October 23, 2018 - CUIMC Celebrates 2018-2019, Issue 2
October 23, 2018 - Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer
October 23, 2018 - Intake of painkillers during pregnancy linked to early puberty in future offspring
October 23, 2018 - ConnectToBrain project seeks to improve techniques for brain stimulation in current clinical use
October 23, 2018 - Polyganics begins first-in-human clinical trial of LIQOSEAL for reducing CSF leakage
October 23, 2018 - Gut bacterial community of healthy adults recovers after short-term exposure to broad-spectrum antibiotics
October 23, 2018 - Lowering systolic blood pressure does not damage the kidneys, shows study
October 23, 2018 - Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
October 23, 2018 - Cardiovascular admissions more common among most deprived
October 23, 2018 - Targeted drug and hormone therapy combination extends breast cancer survival
October 23, 2018 - Map of human liver cells reveals molecular make-up of individual cells
October 23, 2018 - Drugs approved for breast cancer treatment are effective and well tolerated in men
October 23, 2018 - EKF introduces new hand-held lactate analyzer for rapid sports performance monitoring
October 23, 2018 - Researchers identify common genetic connection in lung conditions
October 23, 2018 - Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC
October 23, 2018 - Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer
October 23, 2018 - New discovery may lead to better treatment options for pancreatic cancer patients
October 23, 2018 - FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
October 23, 2018 - Researchers identify immune culprits linked to inflammation and bone loss in gum disease
October 23, 2018 - Despite lower risk factors, black men have higher rates of recidivism
October 23, 2018 - Study finds why pregnant women in mainland China, Hong Kong and Taiwan prefer cesarean delivery
October 23, 2018 - AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis
October 23, 2018 - NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors
October 23, 2018 - Scientists use electron microscope to study chemical transformation in catalytic cross-coupling reaction
October 23, 2018 - Research offers new hope to men who received childhood cancer treatment
October 23, 2018 - New medical navigation system receives international innovation award
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Cannabis oil shown to significantly improve Crohn’s disease symptoms
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
High-Dose Aspirin Preferred for Kawasaki’s

High-Dose Aspirin Preferred for Kawasaki’s

image_pdfDownload PDFimage_print

Action Points

  • Note that this observational study leveraged the differing treatment practices at two hospitals to determine that high-dose aspirin may reduce dependence on IVIG for treatment of Kawasaki disease in children.
  • Be aware that this was not a randomized trial; other treatment practices that differ between the two study hospitals may have influenced the results.

The use of low-dose aspirin in conjunction with a single dose of intravenous immunoglobulin (IVIG) among children with Kawasaki disease was associated with three times the risk of requiring a second IVIG dose compared with high-dose aspirin, a retrospective chart review in two Canadian centers concluded.

In one hospital where low-dose acetylsalicylic acid (ASA; 3 to 5 mg/kg/day) was routinely used, 23% of patients were given a second infusion of IVIG, compared with 8.7% of those treated in another hospital where high-dose ASA (80 to 100 mg/kg/day) was used (P=0.003), according to Anita Dhanrajani, MBBS, of British Columbia Children’s Hospital in Vancouver, and colleagues.

In a multivariable analysis that adjusted for potential confounders including platelet count, age, and C-reactive protein (CRP), the odds ratio for a second IVIG dose with low-dose ASA was 3.2 (95% CI 1.1-9.1, P=0.03), the researchers reported online in Arthritis Care & Research.

Kawasaki disease is an acute vasculitis predominantly affecting children younger than age 5 years, and currently is the most common form of acquired heart disease in developed countries, especially among those of Asian ancestry. The disease is associated with potentially severe cardiac outcomes, particularly the development of coronary artery aneurysms.

The American Heart Association (AHA) first published recommendations for diagnosis and treatment of Kawasaki disease in 1993; these have been revised, most recently in 2017. The recommendations, which favor high-dose aspirin, have been developed to assist clinicians in decision-making regarding treatment with IVIG, ASA, and corticosteroids, but have not been uniformly adopted. While an IVIG dosage of 2 g/kg is standard, the aspirin dose has been varied, with high doses possibly having greater anti-inflammatory effects but low doses being assumed to have better gastrointestinal tolerability.

In addition, IVIG can be costly and should be judiciously used, according to Dhanrajani’s group.

The standard approach used at British Columbia Children’s Hospital (center 1) involves a single IVIG infusion plus aspirin, 3 to 5 mg/kg/day, for 6 weeks, while at Stollery Children’s Hospital in Edmonton (center 2), the aspirin dose is 80 to 100 mg/kg/day until 24 to 48 hours after defervescence.

Some 10% to 20% of children with Kawasaki disease fail to respond to the initial IVIG dose, which is referred to as IVIG resistance. These patients usually are given a second dose, but are at increased risk of coronary complications and may have longer hospital stays and adverse events such as hemolytic anemia.

Therefore, to see if IVIG resistance is influenced by ASA dose, the researchers reviewed 122 charts from the years 2009 to 2014 at center 1 and from 127 at center 2 from 2005 to 2014.

At baseline, patient ages ranged from 33 to 36 months, and almost two-thirds were boys. Asians were significantly more common in center 1 (53.3% versus 13.4%, P<0.001).

The brand of IVIG most often used in center 1 was Gamunex, and a local formulation of 10% IVIG was the most common in center 2.

To determine whether the different time frames in the two centers influenced the results, the researchers conducted a secondary analysis that included patients only seen from 2009 to 2014, finding an incidence of IVIG resistance of 23% in center 1 and 7.3% in center 2.

Among patients requiring a second infusion of IVIG, time between infusions ranged from 25 to 66 hours.

In the main multivariate analysis, ethnicity was not included, because it was assigned based on family name, which can be unreliable because of marriage and mixed ethnicity. However, when Asian ethnicity was added to the analysis, 19.5% of Asian children had IVIG resistance compared with 13.8% of non-Asians, which was not a significant difference, and the odds ratio for low-dose ASA and IVIG resistance was 3.7 (95% CI 1.2-11.6, P=0.02).

The mean hospital stay was 4.1 days in center 1 and 4.7 in center 2. “It is surprising that despite the difference in IVIG resistance, we could not document a difference in length of hospital stay between the two centers. This may be due to differences between the centers in usual practices regarding discharge of patients with Kawasaki disease,” the researchers noted.

Coronary artery aneurysms developed in two patients from center 1 and in six patients from center 2, which was not significantly different. The study was not powered to detect a difference in this outcome, however.

The three times increased odds of a second IVIG dose seen with low-dose ASA represented a 14% absolute increase, and the number needed to treat was seven.

“Until there is better evidence from randomized controlled trials, it seems reasonable to adhere to AHA guidelines and prescribe high-dose ASA in the initial phase of Kawasaki disease,” Dhanrajani’s group concluded.

Among the limitations of the study were its retrospective design and a lack of information about adverse events associated with ASA.

Dhanrajani and co-authors disclosed no relevant relationships with industry.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-04-01T00:00:00-0400

last updated

Tagged with:

About author

Related Articles